Eiger BioPharmaceuticals

Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Its strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients.

David Apelian Ph.D

CEO and Board Member

1 past transactions

Celladon

Acquisition in 2015
Celladon Corporation is a biotechnology company focused on developing molecular therapies for the treatment of heart failure. Founded in 2000 and headquartered in La Jolla, California, the company is known for its product candidates that address key enzyme deficiencies associated with advanced heart failure. One of its primary products, SERCA2a, is an enzyme that plays a crucial role in calcium cycling and contractility in heart muscle cells. Additionally, Celladon is developing MYDICAR, an enzyme replacement therapy aimed at improving heart function in patients suffering from heart failure.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.